Skip to content

Tyra Biosciences, Inc. TYRA Software and Technology Licenses, Net

Software and Technology Licenses, Net at other companies

Incyte logo
IncyteINCY
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
UroGen Pharma logo
UroGen PharmaURGN
BridgeBio Pharma logo
BridgeBio PharmaBBIO
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
Nuvation Bio logo
Nuvation BioNUVB

Other financials

Income statement

See full
Operating income-$42.0M-31.9%
Net income-$39.3M-39.6%
EPS (diluted)-$0.64-36.2%

Balance sheet

See full
Cash & equivalents$85.0M-15.7%
Total debt$5.7M-6.9%
Total equity$387.6M+19.8%
Total assets$412.0M+20.0%

Cash flow

See full
Operating cash flow-$32.6M-27.9%
CapEx$88.0K+529%
Free cash flow-$32.7M-28.2%

Valuation

See full
Market cap$1.81B+318%
Enterprise value$1.73B+397%

Returns & leverage

See full
Return on equity-36.9%+21.1pp
Debt / equity0.0×
Current ratio20.5×-2.3×

Where this comes from

Reported directly by Tyra Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Tyra Biosciences, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tyra Biosciences, Inc.'s software and technology licenses, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tyra Biosciences, Inc.'s software and technology licenses, net?
Tyra Biosciences, Inc. (TYRA) reported software and technology licenses, net of $9.89M in Q1 2026.
How has Tyra Biosciences, Inc.'s software and technology licenses, net changed year-over-year?
Tyra Biosciences, Inc.'s software and technology licenses, net decreased by 5.3% year-over-year, from $10.44M to $9.89M.
What is the long-term trend for Tyra Biosciences, Inc.'s software and technology licenses, net?
Over 5 years (2020 to 2025), Tyra Biosciences, Inc.'s software and technology licenses, net has grown at a 238.1% compound annual growth rate (CAGR), from $21K to $9.27M.